#EBW26 Editorial: ISENET – DiData integrates tissue analytics and biobanking for research-ready infrastructures
This article has 664 words and is a 3-minute read.
The Europe Biobank Week Congress highlights the latest trends and important topics in biobanking and biomolecular resources. It brings together professionals, patients and government officials to exchange ideas and learn from one another. Over four days, attendees can enjoy keynote speeches, join discussions, network and explore exhibits with new technologies and products.
We’ve talked to all our sponsors for 2026 to find out why they value being part of this key in-person event for the global biobanking community. Here’s what ISENET – DiData had to say.
Company description
Integrated Systems Engineering (ISENET) brings decades of expertise in Biobanking Construction and Management. Its founder, Pasquale De Blasio, was a co-founder and the first president of ESBB.
ISENET is a recognised leader in Tissue Microarray (TMA) Technology, delivering advanced solutions for high-throughput biomarker research and precision medicine. Learn more at www.isenet.it.
ISENET is a recognised leader in Tissue Microarray (TMA) Technology, delivering advanced solutions for high-throughput biomarker research and precision medicine. Learn more at www.isenet.it.
DiData is a Swiss provider of advanced laboratory informatics, offering a robust biobanking management system designed to support high-quality biomedical research.
Built on the Di-LIMS platform, the system enables end-to-end management of biospecimens, including donor and consent data, sample registration, processing, storage, and longitudinal tracking.
Di-LIMS ensures full traceability, data integrity, and compliance with biobanking standards (e.g. ISO 20387, GDPR), while supporting complex sample hierarchies, metadata management, and audit trails. DiData’s solution is designed to integrate seamlessly into research workflows, enhancing reproducibility, interoperability, and long-term value of biobank collections. Learn more at www.swissdidata.com
Why does it matter to be at EBW26?
Participation in European Biobank Week (EBW) matters strategically for both ISENET and DiData for several complementary reasons: Strategic visibility & positioning EBW is the leading international forum for biobanking, bringing together biobank directors, researchers, clinicians, regulators and technology providers. Participating positions ISENET and DiData as trusted solution providers aligned with the future of biobanking. Validation of the ISENET–DiData synergy EBW provides a neutral, high-level stage to demonstrate how biobank engineering, automation and LIMS interoperability work together in real-world workflows, strengthening credibility beyond single-vendor narratives. Direct access to decision-makers Most EBW attendees are biobank managers, infrastructure leads and national network coordinators, enabling high-quality discussions around new biobank setups, upgrades, ISO 20387 compliance and digital transformation. Standards, regulation and trends EBW is where best practices, guidelines and emerging regulations are discussed. This allows ISENET and DiData to stay aligned with evolving requirements and to proactively adapt their integrated solutions. Partnerships and EU opportunities EBW facilitates connections with BBMRI-ERIC nodes, national biobank networks and EU project consortia, supporting future collaborations, Horizon Europe proposals and multi-site deployments. Thought leadership With ISENET’s historical role in ESBB and DiData’s strength in biobanking informatics, EBW enables both companies to contribute to shaping the future roadmap of digital interoperable and traceble biobanking.
What new innovation are you bringing or what are you most looking forward to?
At EBW, ISENET and DiData are each introducing major innovations in their respective domains of tissue analytics automation and biobank data infrastructure, which together form a uniquely integrated end-to-end workflow for modern biobanking and translational research.
ISENET presents the Galileo™ TMAtic, a new generation of fully automated Tissue Microarray (TMA) platform. Galileo™ enables high-throughput, standardized, and fully traceable tissue core construction for biomarker discovery, digital pathology, and spatial biology, dramatically increasing reproducibility, scalability, and data quality in tissue-based research.
DiData unveils the next evolution of its biobanking and clinical data platform, including:
- a consolidated SMPL module dedicated to biobanking, embedding international best practices and structured datasets for donor, sample, and collection management,
- a new Electronic Data Capture (EDC) module for clinical trials and research studies, enabling clinical, consent, and outcome data to be captured and governed in a centralized way.
Galileo™ TMAtic and the DiData platform extend digital traceability beyond sample storage into downstream analytical assets. This allows biobanks to operate not as passive repositories, but as active, analysis-ready research infrastructures designed for precision medicine, AI and multi-omics research.